Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy.

ABSTRACT: Rituximab (RTX) is an effective treatment for pemphigus; however, the drug labeling recommends not to use RTX within 1 year before conception.

Objectives

To report pregnancy outcomes of patients with pemphigus who were treated with RTX before or during pregnancy.

Methods

We identified 19 pregnancies with RTX exposure before or during pregnancy. All had previously been advised not to get pregnant within 1 year of RTX administration. The cases were categorized into 3 groups of exposure of within 6 months (group A), between 6 and 12 months (group B), and longer than 12 months of conception (group C). The pregnancy outcomes of different RTX exposure intervals were compared.

Results

Group A included 9 pregnancies, of which 3 had received RTX accidentally after conception. G

SUBMITTER: Dehghanimahmoudabadi A 

PROVIDER: S-EPMC9276145 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature